JAMDA
Volume 11, Issue 7 , Pages 468-474 , September 2010

A Synopsis of Phosphate Disorders in the Nursing Home

  • Xiaolei Shelly Xing, MD

      Affiliations

    • UCLA David Geffen School of Medicine, Los Angeles, CA
    • Corresponding Author InformationAddress correspondence to Xiaolei Shelly Xing, MD, 10070 Valley Boulevard, #101, El Monte, CA 91731.
    • ,
  • Dean T. Yamaguchi, MD

      Affiliations

    • UCLA David Geffen School of Medicine, Los Angeles, CA
    • Greater Los Angeles Veterans Affairs Medical Center, Los Angeles, CA
    • ,
  • Nancy T. Weintraub, MD

      Affiliations

    • UCLA David Geffen School of Medicine, Los Angeles, CA
    • Greater Los Angeles Veterans Affairs Medical Center, Los Angeles, CA

References 

  1. Moe SM. Disorder of calcium, phosphate, magnesium. Prim Care. 2008;35:215–237v–vi
  2. William H, Gil H. Phosphate supplementation for hypophosphatemia and parenteral nutrition. Curr Opin Clin Nutr Metab Care. 2001;4:227–233
  3. Pollak MR, Yu AS, Taylor EN. Disorders of calcium, magnesium and phosphate balance. In:  Brenner BM editors. Brenner and Rector's The Kidney. 8th ed. Philadelphia, PA: Saunders; 2007;p. 602–615
  4. Kuro-o M. Klotho and aging. Biochim Biophys Acta. 2009;1790:1049–1058
  5. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444:770–774
  6. Stubbs JR, Liu S, Tang W, et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblast growth factor 23 null mice. J Am Soc Nephrol. 2007;18:2116–2124
  7. White K, Carn G, Lorenz-Depiereux B, et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF23. Kidney Int. 2001;60:2079–2086
  8. Razzaque M, St-Arnaud R, Taguchi T, Lanske B. FGF23, Vitamin D and calcification: The unholy triad. Nephrol Dial Transplant. 2005;20:2032–2035
  9. Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D – 1 alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol. 2007;293:F1577–F1583
  10. Quarles LD. Evidence for a bone-kidney axis regulating phosphate homeostasis. J Clin Invest. 2003;112:642–646
  11. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol. 2007;18:1637–1647
  12. Krajisnik T, Bjorklung P, Marsell R, et al. FGF23 regulates expression of PTH and 1-alpha hydroxylase in bovine parathyroid cells. J Endocrinol. 2007;197:125–131
  13. Rowe PS, Kumagai Y, Gutierrez G, et al. MEPE has the properties of an osteoblastic phophatonin and minhibin. Bone. 2004;34:303–319
  14. David V, Martin A, Hedge A-M, Rowe PSN. Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator. Endocrinology. 2009;150:4012–4023
  15. Larsson L, Rebel K, Sorbo B. Severe hypophosphatemia—a hospital survey. Acta Med Scand. 1983;214:221–223
  16. Evans B, Crogan N, Armstrong Shultz J. Quality dining in the nursing home: The residents' perspective. J Nutr Elder. 2003;22:1–16
  17. Murer H. Cellular mechanisms in proximal tubular Pi reabsorption: Some answers and more questions. J Am Soc Nephrol. 1992;2:1649–1665
  18. Kawata T, Imanishi Y, Kobayashi K, et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol. 2007;18:2683–2688
  19. Hamid Z, Riggs A, Spencer T, et al. Vitamin D deficiency in residents of academic long-term care facilities despite having been prescribed vitamin D. J Am Med Dir Assoc. 2007;8:71–75
  20. Kagansky N, Levy S, Koren-Morag N, et al. Hypophosphateaemia in old patients is associated with the refeeding syndrome and reduced survival. J Intern Med. 2005;257:461–468
  21. Laaban JP, Waked M, Laromiguiere M, et al. Hypophosphatemia complicating management of acute severe asthma. Ann Intern Med. 1990;112:68–69
  22. Paleologos M, Stone E, Braude S. Persistent, progressive hypophosphataemia after voluntary hyperventilation. Clin Sci (Lond). 2000;98:619–625
  23. Nowack R, Wachtler P. Hypophosphatemia and hungry bone syndrome in a dialysis patient with secondary hyperparathyroidism treated with cinacalcet—proposal for an improved monitoring. Clin Lab. 2006;52:583–587
  24. Fukumoto S. Physiological regulation and disorders of phosphate metabolism. Intern Med. 2008;47:337–343
  25. Munk P, Freedman MH, Greenberg ML, Levinson H. Hemoglobin-oxygen affinity in hypophosphatemic rickets. Acta Paediatr Scand. 1976;65:97–99
  26. De Marchi S, Cecchin E, Basile A, et al. Renal tubular dysfunction in chronic alcohol abuse—Effects of abstinence. N Engl J Med. 1993;329:1927–1934
  27. Singhal PC, Kumar A, Desroches L, et al. Prevalence and predictors of rhabdomyolysis in patients with hypophosphatemia. Am J Med. 1992;92:458–464
  28. Subramanian R, Khardori R. Severe hypophosphatemia. Pathophysiologic implications, clinical presentations, and treatment. Medicine (Baltimore). 2000;79:1–8
  29. Craddock PR, Yawata Y, VanSanten L, et al. Acquired phagocyte dysfunction. A complication of the hypophosphatemia of parenteral hyperalimentation. N Engl J Med. 1974;290:1403–1407
  30. Yawata Y, Hebbel RP, Silvis S, et al. Blood cell abnormalities complicating the hypophosphatemia of hyperalimentation erythrocyte and platelet ATP deficiency associated with hemolytic anemia and bleeding in hyperalimented dogs. J Lab Clin Med. 1974;84:643–653
  31. Gaasbeek A. Meinders E. Hypophosphatemia: An update on its etiology and treatment. Am J Med. 2005;1094–1101
  32. Drezner MK. Disease of abnormal phosphate metabolism. In:  Becker KL,  Bilezikian JP,  Bremmer WJ, et al. editor. Principles and Practice of Endocrinology and Metabolism. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001;p. 662–672
  33. White A, Odedina F, Xiao H, et al. The economic burden of end-stage renal disease with hyperphosphatemia. A Study of Florida medicaid. Disease Management & Health Outcomes. 2006;14:99–106
  34. Locatelli F, Cannata-Andia JB, Drueke TB, et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphatemia. Nephrol Dial Transplant. 2002;17:723–731
  35. Blacher J, Guerin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38:938–942
  36. Braun J, Oldendorf M, Moshage W, et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996;27:394
  37. Wayhs R, Zelinger A, Raggi P. High coronary artery calcium scores pose an extremely elevated risk for hard events. J Am Coll Cardiol. 2002;39:225–230
  38. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:458–464
  39. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68:1815–1824
  40. Leu HJ, Brunner U. Calcified and ossified phlebosclerosis. Vasa. 1992;21:11–14
  41. Li X, Giachelli C. Sodium-dependent phosphate cotransporters and vascular calcification. Curr Opin Nephrol. 2007;16:325–328
  42. Arrambide K, Toto RD. Tumor lysis syndrome. Semin Nephrol. 1993;13:273–280
  43. Llach F, Felsenfeld AJ, Haussler MR. The pathophysiology of altered calcium metabolism in rhabdomyolysis-induced acute renal failure. Interactions of parathyroid hormone, 25hydroxycholecalciferol, and 1,25dihydroxycholecalciferol. N Engl J Med. 1981;305:117–123
  44. Fass R, Do S, Hixson LJ. Fatal hyperphosphatemia following Fleet PhosphoSoda in a patient with colonic ileus. Am J Gastroenterol. 1993;88:929–932
  45. Beloosesky Y, Grinblat J, Weiss A, et al. Electrolyte disorders following oral sodium phosphate administration for bowel cleansing in elderly patients. Arch Intern Med. 2003;163:803–808
  46. Randall AG, Garcia-Webb P, Beilby JP. Interference by haemolysis, icterus and lipaemia in assays on the Beckman Synchron CX5 and methods for correction. Ann Clin Biochem. 1990;27:345–352
  47. Lane JW, Rehak NN, Hortin GL, et al. Pseudohyperphosphatemia associated with high-dose liposomal amphotericin B therapy. Clin Chim Acta. 2008;387:145–149
  48. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk on chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;31:607–617
  49. Giachelli CM. Ectopic calcification: Gathering hard facts about soft tissue mineralization. Am J Pathol. 1999;154:671–675
  50. Fitzgerald PJ, Ports TA, Yock PG. Contribution of localized calcium deposits to dissection after angioplasty. An observational study using intravascular ultrasound. Circulation. 1992;86:322–324
  51. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis. 2000;35:1226–1237
  52. Niskanen LK, Suhonen M, Siitonen O, et al. Aortic and lower limb artery calcification in type 2 (non-insulin-dependent) diabetic patients and non-diabetic control subjects: A five-year follow-up study. Atherosclerosis. 1990;84:61–71
  53. Schucker J, Ward K. Hyperphosphatemia and phosphate binders. Am J Health Syst Pharm. 2005;62:2355–2361
  54. National Kidney Foundation . K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1–201
  55. Sullivan C, Sayre S, Leon J, et al. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: A randomized controlled trial. JAMA. 2009;301:629–635
  56. Qunibi W, Moustafa M, Muenz LR, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The Calcium Acetate Renagel Evaluation-2 (CARE-2). Study. Am J Kidney Dis. 2008;51:952–965
  57. Tonelli M, Wiebe N, Culleton B, et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant. 2007;22:2856–2866
  58. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72:1130–1137
  59. Huybrechts KF, Caro JJ, Wilson D, et al. Value in health: Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. 2005;8:549–561
  60. Finn WF. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol. 2006;65:191–202
  61. Behets GJ, Verberckmoes SC, D'Haese PC, De Broe ME. Lanthanum carbonate: A new phosphate binder. Curr Opin Nephrol Hypertens. 2004;13:403–409
  62. Hutchison AJ, Maes B, Vanwalleghem J, et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: A 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract. 2005;100:20–21
  63. Fine A, Patterson J. Severe hyperphosphatemia following phosphate administration for bowel preparation in patients with renal failure: Two cases and a review of the literature. Am J Kidney Dis. 1997;29:103–105
  64. Beloosesky Y, Grinblat J, Weiss A, et al. Electrolyte disorders following oral sodium phosphate administration for bowel cleansing in elderly patients. Arch Intern Med. 2003;163:803–808
  65. Lichtenstein G. Bowel preparations for colonoscopy: A review. Am J Health Syst Pharm. 2009;66:27–37
  66. Gumurdulu Y, Serin E, Ozer B, et al. Age as a predictor of hyperphosphatemia after oral phosphosoda administration for colon preparation. J Gastroenterol Hepatol. 2004;19:68–72

PII: S1525-8610(09)00373-9

doi: 10.1016/j.jamda.2009.10.007

JAMDA
Volume 11, Issue 7 , Pages 468-474 , September 2010

Article Tools

* Image Usage & Resolution